Literature DB >> 11877342

Adenosine A(2A) receptors in portal hypertension: their role in the abnormal response to adenosine of the cranial mesenteric artery in rabbits.

M T Villa de Brito1, A Canto, J H Duarte Correia, R A Cunha, M C Marques.   

Abstract

1. Adenosine is a regulator of mesenteric vasodilation involved in auto-regulation and post-prandial hyperemia, but the adenosine receptor subtype involved in this relaxant effect is poorly characterized. We have now pharmacologically characterized this receptor in rabbit mesenteric arteries and investigated how this adenosine receptor response changes in portal hypertensive animals since the adenosine response is decreased. 2. The closest non-metabolisable adenosine analogue, 2-chloroadenosine (CADO), the mixed A(1)/A(2) receptor agonist, 5'-ethylcarboxamidoadenosine (NECA), and the selective A(2A) receptor agonist, 2-[4-(2-p-carbonyethyl)phenylamino]-5'-N-ethylcarboxamidoadenosine (CGS 21680) (1 pM -- 1 mM) relaxed noradrenaline pre-contracted arteries with a rank order of potency of CGS 21680 (EC(50)=20 nM) > or = NECA (60 nM)>>CADO (640 nM). 3. The selective A(2A) receptor antagonist, 4-(2-[7-amino-2-(2-furyl)-[1,2,4]-triazolo[2,3-a][1,3,5]-triazin-5-ylamino]ethyl)phenol (ZM 241385, 100 nM), shifted to the right the CADO concentration-response curve. 4. In portal hypertensive animals, there was mainly a decreased potency but also a decreased efficacy of all tested adenosine agonists compared to normal animals. Concomitantly, there was a decreased adenosine plasma level and a decreased binding density of [(3)H]-CGS 21680 and [(3)H]-ZM 241385 to mesenteric artery membranes from portal hypertensive compared to normal rabbits. 5. These results indicate that A(2A) receptor activation is required for the adenosine-induced mesenteric relaxation and that the decreased density of A(2A) receptors may contribute to the decreased relaxation induced by adenosine of mesenteric arteries in portal hypertensive animals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11877342      PMCID: PMC1573239          DOI: 10.1038/sj.bjp.0704575

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

Review 1.  Hypertension due to chronic blockade of P1-purinoceptors.

Authors:  S Guimarães; A Albino-Teixeira
Journal:  J Auton Pharmacol       Date:  1996-12

2.  Evidence for high-affinity binding sites for the adenosine A2A receptor agonist [3H] CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A2A receptors.

Authors:  R A Cunha; B Johansson; M D Constantino; A M Sebastião; B B Fredholm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-02       Impact factor: 3.000

3.  Increased nitric oxide-dependent vasorelaxation in aortic rings of cirrhotic rats with ascites.

Authors:  J Clària; W Jiménez; J Ros; M Rigol; P Angeli; V Arroyo; F Rivera; J Rodés
Journal:  Hepatology       Date:  1994-12       Impact factor: 17.425

4.  ZM241385 is an antagonist of the facilitatory responses produced by the A2A adenosine receptor agonists CGS21680 and HENECA in the rat hippocampus.

Authors:  R A Cunha; M D Constantino; J A Ribeiro
Journal:  Br J Pharmacol       Date:  1997-12       Impact factor: 8.739

5.  Vasodilator responses to nitric oxide are enhanced in mesenteric arteries of portal hypertensive rats.

Authors:  A Heinemann; R E Stauber
Journal:  Eur J Clin Invest       Date:  1996-09       Impact factor: 4.686

6.  Further characterization of the binding of the adenosine receptor agonist [3H]CGS 21680 to rat brain using autoradiography.

Authors:  B Johansson; B B Fredholm
Journal:  Neuropharmacology       Date:  1995-04       Impact factor: 5.250

7.  Activation of two sites by adenosine receptor agonists to cause relaxation in rat isolated mesenteric artery.

Authors:  D J Prentice; S L Payne; S M Hourani
Journal:  Br J Pharmacol       Date:  1997-12       Impact factor: 8.739

8.  Endothelial calcium-calmodulin dependent nitric oxide synthase in the in vitro vascular hyporeactivity of portal hypertensive rats.

Authors:  A C Gadano; P Sogni; S Yang; S Cailmail; R Moreau; P Nepveux; D Couturier; D Lebrec
Journal:  J Hepatol       Date:  1997-03       Impact factor: 25.083

9.  Effects of pH on responses to adenosine, CGS 21680, carbachol and nitroprusside in the isolated perfused superior mesenteric arterial bed of the rat.

Authors:  C R Hiley; F E Bottrill; J Warnock; P J Richardson
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

10.  Vasodilatation produced by adenosine in isolated rat perfused mesenteric artery: a role for endothelium.

Authors:  R Tabrizchi; S M Lupichuk
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-10       Impact factor: 3.000

View more
  5 in total

1.  Adenosine Receptors Influence Hypertension in Dahl Salt-Sensitive Rats: Dependence on Receptor Subtype, Salt Diet, and Sex.

Authors:  Edwin K Jackson; Delbert G Gillespie; Zaichuan Mi; Dongmei Cheng
Journal:  Hypertension       Date:  2018-06-25       Impact factor: 10.190

2.  Functional changes in vascular reactivity to adenosine receptor activation in type I diabetic mice.

Authors:  Hicham Labazi; Bunyen Teng; S Jamal Mustafa
Journal:  Eur J Pharmacol       Date:  2017-12-18       Impact factor: 4.432

3.  Functional and RNA expression profile of adenosine receptor subtypes in mouse mesenteric arteries.

Authors:  Bunyen Teng; Daniel Fil; Stephen L Tilley; Catherine Ledent; Thomas Krahn; S Jamal Mustafa
Journal:  J Cardiovasc Pharmacol       Date:  2013-01       Impact factor: 3.105

4.  Purinergic receptors in the splanchnic circulation.

Authors:  Manuela Morato; Teresa Sousa; António Albino-Teixeira
Journal:  Purinergic Signal       Date:  2008-04-29       Impact factor: 3.765

5.  Impaired function of prejunctional adenosine A1 receptors expressed by perivascular sympathetic nerves in DOCA-salt hypertensive rats.

Authors:  Sutheera Sangsiri; Hua Dong; Gregory M Swain; James J Galligan; Hui Xu
Journal:  J Pharmacol Exp Ther       Date:  2013-02-08       Impact factor: 4.030

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.